MorphoSys AG (NASDAQ:MOR) Q1 2020 Earnings Conference Call - Final Transcript

May 07, 2020 • 08:00 am ET


MorphoSys AG (NASDAQ:MOR) Q1 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen, welcome to MorphoSys First Quarter 2020 Results Conference Call. [Operator Instructions] [Operator Instructions]. [Operator Instructions]

Now I would like to turn the conference over to Dr. Julia Neugebauer. Please go ahead.

Julia Neugebauer

Good afternoon, good morning, and welcome to our Q1 2020 results conference call and webcast. My name is Julia Neugebauer, Director, Corporate Communicate and Investor Relations at MorphoSys. With me on the call today are Jean-Paul Kress, our Chief Executive Officer; Jens Holstein, our Chief Financial Officer; and Malte Peters, our Chief Research and Development Officer. Please note that due to the COVID-19 pandemic, we're dialing in from different locations. So I would like to apologize for any disruptions this might cause. Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward-looking statements concerning the development of MorphoSys' core technologies, the progress of its current research and development programs, our transition to a fully integrated commercial pharmaceutical company and the initiation of additional programs.

Should actual conditions differ from the company's assumptions, actual results and actions may differ from those anticipated, you are therefore cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. You can find the agenda for today's call on slide three. Jean-Paul will start with his opening remarks and will give you an overview on our Q1 2020 highlights. He will then hand over to Jens, who will review the financial results for the first quarter of 2020. Jean-Paul then will close with an outlook for the rest of the year. After the presentation, we will all be available for your questions. You will find the slide deck for this call on our corporate website.

I would now like to hand over to Jean-Paul.

Jean-Paul Kress

Thank you, Julia, and good morning, and good afternoon, everyone. First, I want to acknowledge that this has been an extraordinary quarter for all of us. Global pandemic, economic disruption, like none of us have seen before and, of course, financial volatility. I hope that all of you and your families are safe and healthy, and thank you for joining the call in this circumstances. The safety of our employees and patients are top priorities. As outlined in our press release last month, we activated our business continuity plans to minimize disruption and ensure the health and safety of our teams. With these measures in place, we have been able to move full speed ahead with getting ready for a successful launch of tafasitamab, if approved by the FDA. In a few minutes, I will share an update on the status of our launch preparations. But first, I will start with key highlights from a very positive first quarter. We got off to an excellent start in 2020, and I am happy to report on the progress we have made. Early this year, we signed a global licensing agreement with Incyte of tafasitamab. We have been working closely together for